spectrum β-lactamase (1) Production of L1 and L2 is co-ordinately controlled by AmpR, a LysR-type 23 transcriptional activator and induced during β-lactam challenge of cells (2). Where previously 24 characterised, AmpR regulators have been shown to bind two ligands in a competitive manner (3, 4) . 25
As summarised in Figure 1 , the AmpR activator ligand, an anhydro-muramyl-penta-peptide is produced 26 during β-lactam challenge via the concerted actions of lytic transglycosylases, which release 27 N-acetylglucosamine-anhydro-muramyl-peptides from peptidoglycan (5) and AmpG, a permease that 28 transports them into the cytoplasm (6, 7). NagZ, an enzyme that removes the N-acetylglucosamine 29 moiety is also necessary to release the AmpR activator ligand in some species (8), though not in 30 S. maltophilia (9). The AmpR repressor ligand is a UDP-muramyl-penta-peptide (10). It is produced 31 via sequential addition of amino acids to a UDP-muramyl substrate, via four separate ligase enzymes, 32
MurC (11), MurD (12), MurE (13) and MurF (14), with the last adding a D-alanine/D-alanine dipeptide 33 made by a fifth ligase enzyme, Ddl (15) . Mpl is an enzyme that can ligate a ready-made penta-peptide 34 onto the UDP-muramyl substrate, skipping the MurC, D, E, Ddl and MurF ligation reactions, each of 35 which requires ATP hydrolysis (16). This Mpl catalysed reaction therefore saves considerable amounts 36 of energy for the cell. Its penta-peptide substrate comes from breakdown of 37 anhydro-muramyl-penta-peptides by the peptide amidase AmpD. In this way, breakdown of the 38 anhydro-muramyl-penta-peptide AmpR activator ligand by AmpD is also directly linked to production 39 of the UDP-muramyl-penta-peptide AmpR repressor ligand by Mpl (2, 5, 17, 18) ( Fig. 1) . 40
Ceftazidime is a relatively weak substrate for both L1 and L2 β-lactamases from S. maltophilia, and so 41 many clinical isolates remain ceftazidime susceptible (1). However, mutants that have acquired 42 ceftazidime resistance can easily be identified in the laboratory, and ceftazidime resistant isolates are 43 commonly encountered in the clinic. In most cases, these mutants hyperproduce L1 and L2 (19) . 44
Mutations that reduce AmpD function are known to boost L1/L2 production, because the AmpR 45 activator ligand is broken down much less if AmpD is damaged (20) . Mutations that (presumably) 46 increase peptidoglycan turnover, releasing more muropeptides, also activate L1/L2 production, e.g. 47 those in PBP1A, encoded by mcrA (21) and in the lytic transglycosylase MltD, because this mutation 48 stimulates the net production of lytic transglycosylase activity in the cell (22) . Mutations in AmpR also 49 activate L1/L2 production (4). We have previously characterised ceftazidime resistant, β-lactamase 50 hyper-producing laboratory selected mutants derived from the extremely well studied clinical isolate 51 K279a. One of these mutants, KCAZ14, was wild-type for ampR, ampD, and mcrA (19). To identify 52 the mutation responsible, whole genome resequencing was performed by MicrobesNG (Birmingham, 53 UK) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using 54
Trimmomatic
(23) and assembled into contigs using SPAdes 3.10.1 55 (http://cab.spbu.ru/software/spades/). Assembled contigs were mapped to reference genome for 56 S. maltophilia K279a (24) obtained from GenBank (accession number NC_010943) using 57 progressiveMauve alignment software (25). The only mutation identified in KCAZ14 was a deletion of 58 18 nucleotides in mpl gene, deleting amino acids 141-146 of Mpl. The level of β-lactamase production, 59 measured as previously (19) was similar for the mpl mutant KCAZ14, for an ampD loss of function 60 mutant KCAZ10 (19) and for KM11, an ampR activatory mutant (4) ( Table 1) . To confirm involvement 61 of mpl loss in the β-lactamase hyper-producing, ceftazidime resistant phenotype of KCAZ14, we 62 attempted complementation in trans. K279a mpl was amplified by PCR as previously (19) with primers 63 mpl_F (5'-ACCAGATCCAGGTACCGCC-3'), mpl_R (5'-TCTCACATCCCGTGTAGGACT-3'). 64
The product was blunt-end ligated into pBBRMCS-5 (Gm R ) (26, 27) digested with SmaI and the 65 resulting recombinant plasmid used to transform KCAZ14 to gentamicin resistance (15 µg.mL -1 ) via 66 electroporation. The ceftazidime MIC against KCAZ14(pBBRMCS-5) was 64 µg.mL -1 and reduced to 67 4 µg.mL -1 in KCAZ14(pBBRMCS-5::mpl), the same as the MIC against wild-type K279a. Production 68 of β-lactamase was also reduced to wild-type levels in KCAZ14(pBBRMCS-5::mpl) ( Table 1) adding 69 further confirmation of successful complementation. 70
We have four ceftazidime resistant, β-lactamase hyperproducing clinical S. maltophilia clinical isolates 71 in our collection: isolates 49-6147, 3800 and 98 (19) and ULA-511 (28) (Table1). Isolate 98 has an 72 Insertion Sequence element disrupting ampD (19). Whilst we also found a mutation causing an 73
Ala85Gly change in Mpl, the same mutation is carried by ~5% of S. maltophilia genomes in the 74 Genbank database so is probably insignificant. The other three clinical isolates have mpl mutations. In 75 49-6147, the mutation causes the deletion of amino acids 92-109, which disrupts the conserved 76
Ser-Gly-Pro region (29). In 3800, there is a frameshift at codon 368 and in ULA-511 there is a nonsense 77 mutation at codon 360. 78
The result of Mpl loss in KCAZ14 and these clinical isolates will be a build-up of penta-peptides 79 released by AmpD (Fig. 1) . Even though there are other enzymes that can break down these penta-80 peptides, it seems reasonable to hypothesise that this net accumulation of penta-peptide will affect 81
AmpD activity by feedback inhibition, increasing the concentration of its substrate, the AmpR activator 82 ligand, causing β-lactamase hyper-production (18). 83 This is the first report of mpl disruption causing β-lactamase hyperproduction in S. maltophilia, and to 84 find it in 3/4 clinical isolates was striking. It is also interesting to find that mpl loss of function mutations 85 have been seen to accumulate in Pseudomonas aeruginosa populations carried by people with Cystic 86
Fibrosis during long term colonisation in two separate studies (30, 31) and also in 3/4 patients with 87 P. aeruginosa mediated ventilator associated pneumonia (32). Indeed, mpl mutation has been identified 88 as a cause of AmpC β-lactamase hyperproduction in one P. aeruginosa PAO1 laboratory selected 89 transposon-insertion mutant (33). Whilst this did not dramatically increase β-lactam MICs (33), PAO1 90 is relatively permeable to β-lactams, because it lacks many of the efflux pump/porin altering mutations 91 seen in clinical isolates (34). Therefore, it would seem reasonable to propose that these clinically 92 acquired P. aeruginosa mpl mutations are being selected by β-lactam therapy. We have a small 93 collection of ceftazidime resistant P. aeruginosa clinical isolates, of which 2/5 have previously been 94 confirmed to hyperproduce AmpC (35). Both have a mutation in mpl, according to whole genome 95 sequencing. The mutations in isolates 86-14571 and 73-56826 cause Met297Val and an Arg103His 96 changes in Mpl, respectively. We conclude, therefore, that mpl loss in S. maltophilia and P. aeruginosa 
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